Effect of Avastin in Juxtafoveal Telangiectasias

Telangiectasis Clinical Trial

Official title:

Does Avastin Change Evolution in Juxtafoveal Telangiectasias?

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00406380
• Other study ID #: APEC-0024
• Status: Withdrawn
• Phase: Phase 3
• Start date: September 2006
• Est. completion date: November 2006

Study information

• Verified date: May 2024
• Source: Asociación para Evitar la Ceguera en México
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal Telangiectasias

Description:

After diagnose Yuxtafoveal telangiectasias secondary to Branch Retinal Vein Occlusion and with Idiopathic Ethiology by clinical signs and Fluorescein angiogram (FA)findings we treated patients with Intravitreal Injection of Bevacizumab (2.5mg/0.1ml). We performed a complete ophthalmological evaluation and at baseline and follow-up (1 and 3 months) we evaluate ETDRS Best Corrected visual acuity (BCVA), fluorescein angiogram (FA) and Optical Coherence Tomography (OCT)findings. We found an improvement in visual acuity and reduction of FA leakage and decrease retinal thickness in OCT.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 2006
• Est. primary completion date: September 2006
• Gender: All
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with Telangiectasias secondary to Branch Retinal Vein Occlusion

• Patients with Idiopathic Juxtafoveal Retinal Telangiectasias

Exclusion Criteria:

• Diabetic Retinopathy and Diabetic Macular Edema

• Hypertensive Retinopathy

• Choroidal Neovascularization

Related Conditions & MeSH terms

• Telangiectasis

Intervention

Drug:
• Bevacizumab

Procedure:
• Intravitreal injection of Bevacizumab

Locations

Country	Name	City	State
Mexico	Asociacion para Evitar la Ceguera en Mexico	Mexico	DF

Sponsors (1)

Lead Sponsor	Collaborator
Asociación para Evitar la Ceguera en México

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best corrected Visual Acuity
Primary	Fluorescein Angiogram: Leakage
Primary	Optical Coherence Tomography: Retinal thickness